Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
62 hedge funds and large institutions have $276M invested in Poseida Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 10 closing their positions.
189% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 9
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
11% more funds holding
Funds holding: 56 → 62 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $288M → $276M (-$12.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.33M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4.08M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.52M |
| 5 |
JP Morgan Chase
New York
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.2M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$9.2M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$1.95M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.72M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.62M |
PSTX Hedge Fund Activity: Q1 2021 in Review
62 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q1 2021, worth a combined $276M — down 4.3% from $288M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PSTX positions and 10 closed out — a net gain of 6 holders — while 26 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $12.5M. The largest seller was Vivo Capital, exiting entirely with an estimated $10.2M sold.
- 62 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q1 2021, up from 56 in Q4 2020.
- Funds reported $276M of Poseida Therapeutics, Inc. Common Stock stock for Q1 2021, down 4.3% quarter-over-quarter.
- 16 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q1 2021 and 10 closed out, a net change of +6 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q1 2021 was BlackRock, an estimated $12.5M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q1 2021 was Vivo Capital, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2021.